「pma」の検索結果

Use when the user asks to "optimize my Shopping feed", "fix product disapprovals", "improve product titles/attributes", or "build feed-driven PMax asset groups"; audits and rewrites the Shopping/Performance Max product feed — title/description patterns, required and recommended attributes, GTIN/availability/price hygiene, disapproval triage, and feed-driven asset-group / listing-group structure — informing the ROAS O (Offer) dimension. Not for text ad copy — use ad-creative-builder; not for scoring the account or the RQS — use ad-account-auditor. 商品Feed优化/购物广告Feed/商品标题优化/商品禁投修复

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user asks to "plan my paid account structure", "pick Search vs PMax", "lay out ad groups / asset groups", or "audit paid-vs-organic cannibalization"; designs campaign-type selection, ad-group/asset-group layout, targeting + match types, negative/exclusion hygiene, and a paid↔organic overlap audit, and scores the ROAS A (Audience) dimension + structure. Not for computing the final RQS — use ad-account-auditor; not for budget split — use budget-optimizer; not for organic site architecture — use site-structure-optimizer. 付费广告账户结构/广告系列规划/否定关键词

日本語の概要は準備中です。原文の説明を表示しています。

Prepare FDA/EMA regulatory submissions (IND/NDA/BLA/510(k)/PMA/MAA) in CTD format. Generate module outlines (Modules 1-5), run ICH compliance checks (ALCOA+, E6 GCP, Q1-Q12), verify data integrity, and produce submission-ready dossiers with cover letters and checklists.

日本語の概要は準備中です。原文の説明を表示しています。

Quality control for pooled CRISPR screens covering library representation, Gini index, log-skew, replicate Pearson and Spearman concordance, essentialome precision-recall AUC against CEGv2 (Hart 2017), Cas9 cut-toxicity diagnostics, copy-number amplicon detection (Aguirre 2016 / Munoz 2016), bottleneck propagation through plasmid pool, infection, selection, and endpoint stages, MOI verification, and DepMap-style screen-quality scoring. Use when assessing screen quality before hit calling, deciding whether to repeat or rescue a screen, diagnosing low-confidence hits, choosing between MAGeCK / BAGEL2 / Chronos based on quality grade, picking a normalization strategy from QC signatures, or evaluating whether an in-vivo screen retained adequate library complexity.

日本語の概要は準備中です。原文の説明を表示しています。

Constructs and validates polygenic risk scores using LDpred2-auto, SBayesRC, MegaPRS, PRS-CS, PROSPER, MUSSEL, BridgePRS, JointPRS, PRSmix, or PGS Catalog Calculator with ancestry-aware reference panels (HapMap3, UKB-LD), ancestry-conditional calibration, and PRS-RS reporting standards. Use when computing PRS for cohorts, applying absolute-risk transformation, assessing cross-ancestry portability (Martin 2017 / Ding 2023 continuous ancestry), or auditing PRS manuscripts against the 22-item PRS-RS reviewer checklist.

日本語の概要は準備中です。原文の説明を表示しています。

Corrects the gene-independent copy-number artifact in CRISPR-Cas9 screens (Aguirre 2016 / Munoz 2016 Cancer Discov) where amplified loci appear essential from DNA-damage burden of simultaneous cuts. Covers the gene-independent DNA-damage / G2-arrest mechanism, CRISPRcleanR (Iorio 2018) unsupervised pre-hoc correction, CERES (Meyers 2017) joint CN + gene-effect model, Chronos (Dempster 2021) DepMap-standard population-dynamics + CN model with lowest residual bias, the decision tree by data availability, the Spearman LFC-vs-CN diagnostic, focal-amplification examples (ERBB2 in HER2+, MYC in colorectal, FGFR1 in head and neck), and CRISPRi/a alternatives that bypass the artifact. Use when screening cancer cell lines, diagnosing essentiality at amplified loci, choosing CRISPRcleanR / CERES / Chronos, deciding whether CN correction is needed before MAGeCK / BAGEL2 / drugZ, or switching from Cas9 to CRISPRi.

日本語の概要は準備中です。原文の説明を表示しています。

Batch effect correction for CRISPR screens covering ComBat empirical-Bayes, RUV, SVA, control-sgRNA normalization, and the model-based alternative of including batch as a covariate in MAGeCK MLE or Chronos. Covers screen-specific batch sources (passage cohort, library lot, infection day, sequencing run, Cas9 lot, FBS lot), PCA + variance-decomposition diagnostic to decide if correction is needed, when correction harms biology by over-correcting condition into batch, limma removeBatchEffect for visualization-only correction, and relationship to multi-condition design matrices. Use when combining screens for joint analysis, when passage cohort confounds biology, when DepMap-style panels need Chronos with batch covariates, when picking ComBat vs RUV, or when correction harms biology and should be replaced with explicit covariate modeling.

日本語の概要は準備中です。原文の説明を表示しています。

Queries gnomAD v4 (807k samples), v3, v2.1.1, and constraint metrics with grpmax FAF95, bottleneck-group exclusion, LOEUF interpretation, SV/CNV/mtDNA catalogs, and Whiffin max-credible-AF framework. Use when filtering rare variants, applying ACMG BS1/BA1, ranking genes by LoF intolerance, or selecting between v2 (GRCh37 + chrX/Y constraint) and v4 (GRCh38 + 807k samples).

日本語の概要は準備中です。原文の説明を表示しています。

Build CarPlay-enabled apps using the CarPlay framework. Use when creating navigation, audio, communication, EV charging, parking, or food ordering apps for the car display, working with CPTemplateApplicationScene, CPInterfaceController template hierarchies, CPListTemplate, CPMapTemplate, CPNowPlayingTemplate, configuring CarPlay entitlements, or integrating with CarPlay Simulator for testing.

日本語の概要は準備中です。原文の説明を表示しています。

Manage MATLAB packages with the in-product MATLAB Package Manager (mpm) on MATLAB R2026b or later: install, uninstall, update, search, or inspect packages; declare package dependencies in a matlab.toml project; install a shareable .mltbx package; or manage repositories. Covers dependency-resolution errors and anything involving mpminstall / mpmuninstall / mpmupdate / mpmlist / mpmsearch / mpmAddRepository / matlab.mpm.*. MATLAB *packages* are distinct from MathWorks products, toolboxes, and support packages: a bare "what packages are installed?" means MPM packages (mpmlist / matlab.mpm.Package) — this skill — unless the user explicitly says products, toolboxes, or support packages. NOT for installing MATLAB, Simulink, or toolboxes from a shell via the standalone mpm executable (the OS-level product installer), nor for listing installed products / toolboxes (ver, installedAddons) — use matlab-install-products for those.

日本語の概要は準備中です。原文の説明を表示しています。

Access Cancer Dependency Map project data for functional genomics

日本語の概要は準備中です。原文の説明を表示しています。

Senior Regulatory Affairs Manager for HealthTech and MedTech. Use for regulatory strategy, FDA 510(k)/PMA/De Novo submissions, EU MDR CE marking, global market access, and regulatory intelligence.

日本語の概要は準備中です。原文の説明を表示しています。

Plan or audit paid ads with current platform rules and benchmarks: Google PMax/AI Max, Meta, retail. "should we use Performance Max"

日本語の概要は準備中です。原文の説明を表示しています。

Classes and statistical methods for large SNP association studies. This extends the earlier snpMatrix package, allowing for uncertainty in genotypes.

日本語の概要は準備中です。原文の説明を表示しています。

Programmatic inbox management for Smartlead. Enable/disable warmup with correct ramp settings, set signatures in bulk, tag inboxes (active vs insurance), and pull inbox health dashboards. Use after creating a new batch of inboxes via /zapmail-domain-setup-public, or when managing an existing Smartlead account at scale. Triggers on "turn on warmup", "set signatures", "tag inboxes", "inbox health", "set up new inboxes".

日本語の概要は準備中です。原文の説明を表示しています。

Plan, build, and optimize Google Ads campaigns — Search, Shopping, Performance Max, Display, and YouTube — including keyword research, match types, bidding strategy, Quality Score, ad extensions, conversion tracking, and ROAS optimization. Use when the user says "Google Ads", "Google advertising", "Google campaign", "search ads", "Google Shopping", "Performance Max", "PMax", "Google Display", "YouTube ads", "keyword targeting", "Google Ads strategy", "Google Ads optimization", "Google Ads account", "Google Ads not working", "search campaign", "Quality Score", "bidding strategy", "Google conversion tracking", or wants to run or improve paid advertising on Google.

日本語の概要は準備中です。原文の説明を表示しています。

Query openFDA API for drugs, devices, adverse events, recalls, regulatory submissions (510k, PMA), substance identification (UNII), for FDA regulatory data analysis and safety research.

日本語の概要は準備中です。原文の説明を表示しています。

Device-track catalyst analysis: 510(k), PMA, and De Novo decision events, CMS coverage and NTAP milestones, recalls and watch actions as risk signals, and post-market surveillance obligations — dated, verified, and sized per event for any medtech ticker or watchlist.

日本語の概要は準備中です。原文の説明を表示しています。

Think and work like an expert Mineralogist. Use when a task calls for Mineralogist judgment. Reasons from crystal chemistry, Pauling coordination, and converging optics–XRD/Raman–EPMA evidence; uses RRUFF/Mindat/AMCSD and CNMNC Checklist 2025 while treating preferred orientation, clay EG/heat triads, metamict amorphization, and QEMSCAN library bias as first-class failure modes.

日本語の概要は準備中です。原文の説明を表示しています。

Think and work like an expert Food Microbiologist. Use when a task calls for Food Microbiologist judgment. Reasons from food as a hurdle-governed matrix of water activity, pH, and redox through BAM/ISO reference methods, c/n/m/M sampling plans, PMA-v-qPCR, and ComBase kinetics while treating VBNC and injured cells, post-process contamination, matrix inhibition, and unconfirmed PCR hits as first-class failure modes.

日本語の概要は準備中です。原文の説明を表示しています。

Think and work like an expert Cancer Biologist. Use when a task calls for Cancer Biologist judgment. Reasons from hallmark capabilities, clonal evolution, and TME context; separates driver from passenger, cell-autonomous from stromal mechanisms, and 2D artifacts from PDO/PDX-validated dependencies using TCGA, DepMap, OncoKB, and REMARK-grade biomarker logic.

日本語の概要は準備中です。原文の説明を表示しています。

Corrects the gene-independent copy-number artifact in CRISPR-Cas9 screens (Aguirre 2016 / Munoz 2016 Cancer Discov) where amplified loci appear essential from DNA-damage burden of simultaneous cuts. Covers the p53-dependent G2-arrest mechanism, CRISPRcleanR (Iorio 2018) unsupervised pre-hoc correction, CERES (Meyers 2017) joint CN + gene-effect model, Chronos (Dempster 2021) DepMap-standard population-dynamics + CN model with lowest residual bias, the decision tree by data availability, the Spearman LFC-vs-CN diagnostic, focal-amplification examples (ERBB2 in HER2+, MYC in colorectal, FGFR1 in head and neck), and CRISPRi/a alternatives that bypass the artifact. Use when screening cancer cell lines, diagnosing essentiality at amplified loci, choosing CRISPRcleanR / CERES / Chronos, deciding whether CN correction is needed before MAGeCK / BAGEL2 / drugZ, or switching from Cas9 to CRISPRi.

日本語の概要は準備中です。原文の説明を表示しています。

Batch effect correction for CRISPR screens covering ComBat empirical-Bayes, RUV, SVA, control-sgRNA normalization, and the model-based alternative of including batch as a covariate in MAGeCK MLE or Chronos. Covers screen-specific batch sources (passage cohort, library lot, infection day, sequencing run, Cas9 lot, FBS lot), PCA + variance-decomposition diagnostic to decide if correction is needed, when correction harms biology by over-correcting condition into batch, limma removeBatchEffect for visualization-only correction, and relationship to multi-condition design matrices. Use when combining screens for joint analysis, when passage cohort confounds biology, when DepMap-style panels need Chronos with batch covariates, when picking ComBat vs RUV, or when correction harms biology and should be replaced with explicit covariate modeling.

日本語の概要は準備中です。原文の説明を表示しています。

Prioritize drug targets from a ranked gene list (e.g., scRNA-seq DE output) by orchestrating parallel API queries against UniProt, OpenTargets (with integrated DepMap CRISPR essentiality + gnomAD constraint), PubMed, the Human Protein Atlas (HPA), and ChEMBL tool compounds, then re-ranking by a composite score combining protein localization, druggability, disease genetics, tissue specificity (safety), focus-cell-type expression, CRISPR essentiality, LoF safety constraint, and research maturity. Use whenever the user wants to filter, triage, prioritize, or "do due diligence" on a list of candidate genes for drug discovery, especially after a DE / DEG analysis when they say things like "which of these should I follow up on", "filter for druggable targets", "make a target dossier", "rank these for tractability", "annotate these genes for druggability", or "build a target report". Trigger even when the user says just "filter these candidate genes" or hands over a CSV from a DE pipeline.

日本語の概要は準備中です。原文の説明を表示しています。